BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 8030440)

  • 1. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
    Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
    J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
    Body JJ; Dumon JC; Thirion M; Cleeren A
    J Bone Miner Res; 1993 Jun; 8(6):701-6. PubMed ID: 8328312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypercalcemia of malignancy: a study of clinical features and relationships among circulating levels of calcium, parathyroid hormone and parathyroid hormone-related peptide.
    Sriussadaporn S; Phoojaroenchanachai M; Ploybutr S; Plengvidhya N; Peerapatdit T; Nitiyanant W; Vannasaeng S; Vichayanrat A
    J Med Assoc Thai; 2007 Apr; 90(4):663-71. PubMed ID: 17487119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
    Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
    J Clin Endocrinol Metab; 1993 Mar; 76(3):801-3. PubMed ID: 8445039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raised plasma concentrations of parathyroid hormone related peptide in hypercalcemic multiple myeloma.
    Horiuchi T; Miyachi T; Arai T; Nakamura T; Mori M; Ito H
    Horm Metab Res; 1997 Sep; 29(9):469-71. PubMed ID: 9370119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
    Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.
    Horwitz MJ; Tedesco MB; Sereika SM; Syed MA; Garcia-Ocaña A; Bisello A; Hollis BW; Rosen CJ; Wysolmerski JJ; Dann P; Gundberg C; Stewart AF
    J Bone Miner Res; 2005 Oct; 20(10):1792-803. PubMed ID: 16160737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parathyroid hormone (PTH)-related protein, PTH, and 1,25-dihydroxyvitamin D in dogs with cancer-associated hypercalcemia.
    Rosol TJ; Nagode LA; Couto CG; Hammer AS; Chew DJ; Peterson JL; Ayl RD; Steinmeyer CL; Capen CC
    Endocrinology; 1992 Sep; 131(3):1157-64. PubMed ID: 1505457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.
    Horwitz MJ; Tedesco MB; Sereika SM; Hollis BW; Garcia-Ocaña A; Stewart AF
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1603-9. PubMed ID: 12679445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of parathyroid hormone on renal calbindin-D28k.
    Hemmingsen C; Staun M; Lewin E; Nielsen PK; Olgaard K
    J Bone Miner Res; 1996 Aug; 11(8):1086-93. PubMed ID: 8854244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical utility of parathyroid hormone-related peptide in the assessment of hypercalcemia.
    Fritchie K; Zedek D; Grenache DG
    Clin Chim Acta; 2009 Apr; 402(1-2):146-9. PubMed ID: 19168044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas.
    Mitlak BH; Hutchison JS; Kaufman SD; Nussbaum SR
    Horm Metab Res; 1991 Jul; 23(7):344-6. PubMed ID: 1663481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
    Blind E; Raue F; Meinel T; Wüster C; Ziegler R
    Horm Metab Res; 1993 Jan; 25(1):40-4. PubMed ID: 8428711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of estrogen on daylong circulating calcium, phosphorus, 1,25-dihydroxyvitamin D, and parathyroid hormone in postmenopausal women.
    Packer E; Holloway L; Newhall K; Kanwar G; Butterfield G; Marcus R
    J Bone Miner Res; 1990 Aug; 5(8):877-84. PubMed ID: 2173358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
    Nakayama Y; Okuno S; Miki T; Nishizawa Y; Morii H
    Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1294-9. PubMed ID: 1291340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia.
    Audran M; Minebois-Villégas A; Lortholary A; Legrand E; Pascaretti C; Giraud P; Subra JF; Boasson M; Jallet P
    Rev Rhum Engl Ed; 1995 Mar; 62(3):189-96. PubMed ID: 7788336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroid-hormone-related peptide in hematologic malignancies.
    Kremer R; Shustik C; Tabak T; Papavasiliou V; Goltzman D
    Am J Med; 1996 Apr; 100(4):406-11. PubMed ID: 8610726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population.
    Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC
    J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
    Haq M; Kremer R; Goltzman D; Rabbani SA
    J Clin Invest; 1993 Jun; 91(6):2416-22. PubMed ID: 8514854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.